Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds Sara AbdelfatahEdmond FleischerThomas Efferth PRECLINICAL STUDIES 15 March 2019 Pages: 1 - 9
Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent Ghenwa NasreddineMirvat El-SibaiRalph J. Abi-Habib PRECLINICAL STUDIES 18 March 2019 Pages: 10 - 19
Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway Yufan ZhengHairong ChenHongwei Zhang PRECLINICAL STUDIES 18 March 2019 Pages: 20 - 28
Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties Jing-De WuYing-Jie CuiZhao-Peng Liu PRECLINICAL STUDIES 18 March 2019 Pages: 29 - 38
Discovery of a pyrimidine compound endowed with antitumor activity Ludovica TaglieriFrancesco SaccolitiSusanna Scarpa PRECLINICAL STUDIES 21 March 2019 Pages: 39 - 49
Emodin induced necroptosis in the glioma cell line U251 via the TNF-α/RIP1/RIP3 pathway Jiabin ZhouGenhua LiFeng Jin PRECLINICAL STUDIES Open access 28 March 2019 Pages: 50 - 59
MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway Yang LiuJuan TanLimin Chen PRECLINICAL STUDIES 30 March 2019 Pages: 60 - 69
Assessment of the cytotoxic effects of aporphine prototypes on head and neck cancer cells Dorival Mendes Rodrigues-JuniorNicolie Melanie de Almeida PontesAndré Luiz Vettore PRECLINICAL STUDIES 17 May 2019 Pages: 70 - 78
Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia Jincheng YangKun ChenWeihua Wang PRECLINICAL STUDIES 04 July 2019 Pages: 79 - 91
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells Paola OrlandiDaniela GentileGuido Bocci SHORT REPORT 01 June 2019 Pages: 92 - 98
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors Jih-Hsiang LeeTom Wei-Wu ChenChia-Chi Lin PHASE I STUDIES Open access 02 March 2019 Pages: 99 - 110
A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study Mitsukuni SuenagaTakeru WakatsukiKensei Yamaguchi PHASE I STUDIES 06 March 2019 Pages: 111 - 119
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors Lee S. RosenRobert WesolowskiAnthony W. Tolcher PHASE I STUDIES 18 March 2019 Pages: 120 - 130
The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants Maulik PatelJoseph ChenYazdi K. Pithavala Review 14 November 2019 Pages: 131 - 139
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study Kenichi InoueShigenori E. Nagaifor the SBCCSG-14 investigators PHASE II STUDIES Open access 10 July 2019 Pages: 140 - 147
A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstline induction chemotherapy in extensive stage small cell lung cancer Hao LuoLiang ZhangNan Dai PHASE II STUDIES Open access 09 August 2019 Pages: 148 - 159
Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors Sadal RefaeJocelyn GalEsma Saada-Bouzid PHASE II STUDIES 11 August 2019 Pages: 160 - 171
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan Sadahisa OgasawaraYoshihiko OokaNaoya Kato SHORT REPORT 06 June 2019 Pages: 172 - 180
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach Stergios BoussiosPeeter KarihtalaNicholas Pavlidis REVIEW 24 October 2019 Pages: 181 - 193
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation Takahisa KawamuraHirotsugu KenmotsuToshiaki Takahashi SHORT REPORT Open access 10 June 2019 Pages: 194 - 201
The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment Yuan-Hung KuoJing-Houng WangChien-Hung Chen PHASE III STUDIES 08 November 2019 Pages: 202 - 210
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study Hayato KawachiMotohiro TamiyaToru Kumagai PHASE III STUDIES 30 November 2019 Pages: 211 - 218